SynaptiCore Therapeutics is advancing a non-hallucinogenic indole derivative. Designed to selectively restore synaptic density, our candidate aims to address synaptic atrophy underlying complex neurodegenerative conditions.
This page summarizes computational parameters prior to wet-lab synthesis. SMILES notation and synthetic routes are strictly confidential under Mutual NDA.
The objective of SynaptiCore Therapeutics is structural disease modification. Current psychiatric and neurodegenerative treatments often act as temporary symptom management. By focusing on structural neuroplasticity, we aim to address the physical atrophy of dendritic spines.
In-silico molecular docking was performed against the 5-HT2A receptor (PDB: 6WHA), demonstrating favorable binding kinetics and fulfilling Lipinski's parameters via SwissADME. By computationally refining a known neurotrophic core, we engineered SC-01: a modified indole scaffold designed for optimal BBB penetration and targeted receptor engagement, without the hallucinogenic liability.
Our targeted approach aims to stimulate intracellular pathways (such as mTOR) to restore mature, functional connections in atrophied neural networks.
SC-01 utilizes a strategically modified indole scaffold. By introducing a trifluoromethoxy (OCF3) substitution, we successfully elevated predicted lipophilicity for BBB crossing while protecting the core from metabolic degradation.
Computational docking (via PyRx/AutoDock Vina) confirms stable, high-affinity interaction with the orthosteric site, allowing us to predict powerful target engagement prior to in-vitro assays.
Detailed synthetic routes, exact receptor docking poses, and precise scaffold modifications are protected intellectual property.
Request Information via NDASynaptiCore has successfully completed the computational evaluation phase. We are actively engaging Contract Research Organizations (CROs) via Science Exchange to execute the physical synthesis and validate the in-vitro efficacy of our lead compound.
Synthetic Considerations: While the in-silico profile is highly favorable (SA Score: ~2.5), we anticipate standard challenges in the multi-step custom synthesis, particularly regarding intermediate purification and potential steric hindrance around the trifluoromethoxy (OCF3) substitution. We are seeking CRO partners equipped to navigate these specific synthetic hurdles.
We are seeking proposals for the following sequence: